SCHEMBL4097869

SCHEMBL4097869

CON(C)C(=O)c1ccc(Cl)c(C)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MLYCD O95822 1/20 0.45
SLC6A3 Q01959 1/20 0.45
TAS1R3 Q7RTX0 1/20 0.43
TAS1R1 Q7RTX1 1/20 0.43
TAS1R2 Q8TE23 1/20 0.43
MAOA P21397 1/20 0.42
MAOB P27338 1/20 0.42
GPR183 P32249 1/20 0.41
MCL1 Q07820 1/20 0.41
ALDH1A1 P00352 2/20 0.39
GAA P10253 1/20 0.39
MAPT P10636 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
PKM P14618 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8988251 0.87 MLYCD (0.45) MLYCDSLC6A3ALDH1A1MAPTL3MBTL1
SCHEMBL2655175 0.86 SLC6A3 (0.54) MLYCDSLC6A3MAPTMEN1KMT2A
SCHEMBL4843412 0.84 MLYCD (0.49) MLYCDTAS1R3TAS1R1ALDH1A1GAA
SCHEMBL13724877 0.83 MLYCD (0.45) MLYCDSLC6A3ALDH1A1MEN1KMT2A
SCHEMBL185480 0.82 MEN1 (0.48) MLYCDSLC6A3ALDH1A1MEN1KMT2A
SCHEMBL6988786 0.82 MLYCD (0.44) MLYCDSLC6A3ALDH1A1MEN1KMT2A
SCHEMBL5604944 0.82 CYP1A2 (0.44) MLYCDSLC6A3ALDH1A1MAPTMEN1
SCHEMBL7571088 0.81 GPBAR1 (0.50) MLYCDSLC6A3
SCHEMBL2282312 0.80 TAS1R3 (0.47) MLYCDTAS1R3TAS1R1ALDH1A1MAPT
SCHEMBL2272338 0.80 MLYCD (0.45) MLYCDSLC6A3ALDH1A1MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090221645-A1 Dihydroimidazothiazole Derivatives PROSIDION LIMITED (GB) 2009-09-03 US disclosed
US-20090221645-A1 Dihydroimidazothiazole Derivatives PROSIDION LIMITED (GB) 2009-09-03 US disclosed
US-20090221645-A1 Dihydroimidazothiazole Derivatives PROSIDION LIMITED (GB) 2009-09-03 US disclosed
EP-1851232-A2 DIHYDROIMIDAZOTHIAZOLE DERIVATIVES Prosidion Limited (GB) 2007-11-07 EP disclosed
WO-2006085118-A2 DIHYDROIMIDAZOTHIAZOLE DERIVATIVES PROSIDION LIMITED (GB) 2006-08-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221645-A1 Dihydroimidazothiazole Derivatives TPH1, HTR3B, HTR1A MLYCD 1408/4885SLC6A3 38/4885TAS1R3 1110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.